Posts

AstraZeneca seals near $1.8B renal disease pact with CSPC

on

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

on

GSK acquires Siran Biotechnology for $1 billion to expand beyond weight-loss with siRNA therapy

on

GSK Acquires $1B siRNA Deal from SiranBio for Obesity and Cardiometabolic Disease Treatment

on

After Tumultuous Year, Sarepta Plots Rebound with Early Data on RNA Therapies

on

Madrigal Pharmaceuticals Secures $4.4B Deal for Six Preclinical siRNA Programs Targeting MASH from Ribo Life Science

on

Argo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic BW-20829 for Elevated Lp(a)

on

Wave Life Sciences Obesity Biomarker Data Raise Hopes for Future Readouts

on

Novartis Again Partners with Argo Biopharma in $5.2B+ RNAi Cardiovascular Deal

on

Regeneron Reports Phase 3 Success for Cemdisiran in Rare Disease Generalized Myasthenia Gravis

on

Sarepta Shifts Focus to siRNA Platform, Lays Off 500 After Elevidys Receives Black Box Warning

on

CRISPR Therapeutics Partners with Sirius for siRNA Therapies, Expanding Beyond Gene Editing

on